The 12-month price targets, analyzed by analysts, offer insights with an average target of $508.38, a high estimate of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

We recently compiled a list of the 12 Best Biotech Stocks To Invest In According To Hedge Funds. In this article, we are ...

The conventional wisdom is that there are two important aspects of timing in investing: when to buy a stock and when to sell ...

According to Benzinga Pro, Vertex Pharmaceuticals's peer group average for short interest as a percentage of float is 6.15%, ...

Here are three reasons to buy Vertex Pharmaceuticals stock like ... This ratio factors in the potential for the company's products awaiting approvals and its late-stage pipeline.

Three Motley Fool contributors think they've identified dirt-cheap healthcare stocks to buy right now. Here's why they picked CRISPR Therapeutics (NASDAQ: CRSP), Gilead Sciences (NASDAQ: GILD), and ...

In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), ...

Analysts at Precedence Research expect the gene-editing market to grow 15.7% annually and reach $29.9 billion by 2032, ...

Vertex Pharmaceuticals Incorporated (VRTX) stock saw a modest uptick, ending the day at $485.37 which represents a slight increase of $6.72 or 1.40% from the prior close of $478.65. The stock opened ...

No patients have received Casgevy, CRISPR Therapeutics and Vertex Pharmeceuticals’ recently approved sickle cell gene therapy ...